Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNeuropharmacology

Characterization of COR627 and COR628, Two Novel Positive Allosteric Modulators of the GABAB Receptor

M. Paola Castelli, Angelo Casu, Paola Casti, Carla Lobina, Mauro A. M. Carai, Giancarlo Colombo, Maurizio Solinas, Daniela Giunta, Claudia Mugnaini, Serena Pasquini, Andrea Tafi, Simone Brogi, Gian Luigi Gessa and Federico Corelli
Journal of Pharmacology and Experimental Therapeutics March 2012, 340 (3) 529-538; DOI: https://doi.org/10.1124/jpet.111.186460
M. Paola Castelli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angelo Casu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paola Casti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carla Lobina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mauro A. M. Carai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giancarlo Colombo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maurizio Solinas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Giunta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudia Mugnaini
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Serena Pasquini
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Tafi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simone Brogi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gian Luigi Gessa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Federico Corelli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The potential efficacy of GABAB receptor agonists in the treatment of pain, drug addiction, epilepsy, cognitive dysfunctions, and anxiety disorders is supported by extensive preclinical and clinical evidence. However, the numerous side effects produced by the GABAB receptor agonist baclofen considerably limit the therapeutic use of this compound. The identification of positive allosteric modulators (PAMs) of the GABAB receptor may constitute a novel approach in the pharmacological manipulation of the GABAB receptor, leading to fewer side effects. The present study reports the identification of two novel compounds, methyl 2-(1-adamantanecarboxamido)-4-ethyl-5-methylthiophene-3-carboxylate (COR627) and methyl 2-(cyclohexanecarboxamido)-4-ethyl-5-methylthiophene-3-carboxylate (COR628), which act as GABAB PAMs in 1) rat cortical membranes and 2) in vivo assay. Both compounds potentiated GABA- and baclofen-stimulated guanosine 5′-O-(3-[35S]thio)-triphosphate binding to native GABAB receptors, while producing no effect when given alone. GABA concentration-response curves in the presence of fixed concentrations of COR627 and COR628 revealed an increase of potency of GABA rather than its maximal efficacy. In radioligand binding experiments [displacement of the GABAB receptor antagonist, 3-N-[1-((S)-3,4dichlorophenyl)-ethylaminol]-2-(S)hydroxypropyl cyclo-hexylmethyl phosphinic acid ([3H]CGP54626)], both COR627 and COR628 increased the affinity of high- and low-affinity binding sites for GABA, producing no effect when administered alone up to a concentration of 1 mM. In vivo experiments indicated that pretreatment with per se ineffective doses of COR627 and COR628 potentiated the sedative/hypnotic effect of baclofen. In conclusion, COR627 and COR628 may represent two additional tools for use in investigating the roles and functions of positive allosteric modulatory binding sites of the GABAB receptor.

Footnotes

  • This work was partially supported by Regione Autonoma della Sardegna [Grant L.R.N. 7/07, project code CRP2_6] (to D.G.) and Compagnia di San Paolo “Programma Neuroscienze 2008/09,” Turin, Italy (to G.C.).

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

    http://dx.doi.org/10.1124/jpet.111.186460.

  • ABBREVIATIONS:

    GPCR
    G protein-coupled receptor
    mGlu
    metabotropic glutamate
    PAM
    positive allosteric modulator
    CGP7930
    3,5-bis(1,1-dimethylethyl)-4-hydroxy-β,β-dimethyl-benzenepropanol
    GS39783
    N,N′-dicyclopentyl-2-(methylthio)-5-nitro-4,6-pyrimidinediamine
    BHF177
    N-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-yl]-2-methyl-5-[4-(trifluoromethyl)phenyl]-4-pyrimidinamine
    rac-BHFF
    (R,S)-5,7-di-tertbutyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one
    CGP54626
    3-N-[1-((S)-3,4dichlorophenyl)-ethylaminol]-2-(S)hydroxypropyl cyclo-hexylmethyl phosphinic acid
    GTPγS
    guanosine 5′-O-(3-thio)-triphosphate
    COR627
    methyl 2-(1-adamantanecarboxamido)-4-ethyl-5-methylthiophene-3-carboxylate
    COR628
    methyl 2-(cyclohexanecarboxamido)-4-ethyl-5-methylthiophene-3-carboxylate
    LORR
    loss of righting reflex
    ANOVA
    analysis of variance.

  • Received July 27, 2011.
  • Accepted November 28, 2011.
  • Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 340 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 340, Issue 3
1 Mar 2012
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Characterization of COR627 and COR628, Two Novel Positive Allosteric Modulators of the GABAB Receptor
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNeuropharmacology

COR627 and COR628: Two Novel GABAB PAMs

M. Paola Castelli, Angelo Casu, Paola Casti, Carla Lobina, Mauro A. M. Carai, Giancarlo Colombo, Maurizio Solinas, Daniela Giunta, Claudia Mugnaini, Serena Pasquini, Andrea Tafi, Simone Brogi, Gian Luigi Gessa and Federico Corelli
Journal of Pharmacology and Experimental Therapeutics March 1, 2012, 340 (3) 529-538; DOI: https://doi.org/10.1124/jpet.111.186460

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleNeuropharmacology

COR627 and COR628: Two Novel GABAB PAMs

M. Paola Castelli, Angelo Casu, Paola Casti, Carla Lobina, Mauro A. M. Carai, Giancarlo Colombo, Maurizio Solinas, Daniela Giunta, Claudia Mugnaini, Serena Pasquini, Andrea Tafi, Simone Brogi, Gian Luigi Gessa and Federico Corelli
Journal of Pharmacology and Experimental Therapeutics March 1, 2012, 340 (3) 529-538; DOI: https://doi.org/10.1124/jpet.111.186460
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Disease-Modifying Effects of Neurosteroids in Post-SE Models
  • Lacosamide and Rufinamide Against SE
  • A pediatric rat model of OP-induced status epilepticus
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics